1. Home
  2. PBLS vs PK Comparison

PBLS vs PK Comparison

Compare PBLS & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$28.58

Market Cap

3.4B

Sector

Health Care

ML Signal

N/A

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

N/A

Current Price

$15.73

Market Cap

3.1B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
PBLS
PK
Founded
2015
1946
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.1B
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
PBLS
PK
Price
$28.58
$15.73
Analyst Decision
Strong Buy
Hold
Analyst Count
6
18
Target Price
★ $41.40
$16.59
AVG Volume (30 Days)
1.1M
★ 4.2M
Earning Date
11-17-2026
11-04-2026
Dividend Yield
N/A
★ 6.43%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.19
Revenue
N/A
★ $2,791,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.17
$2.53
P/E Ratio
★ N/A
$58.48
Revenue Growth
N/A
★ 2.35
52 Week Low
$22.66
$9.84
52 Week High
$42.49
$17.14

Technical Indicators

Market Signals
Indicator
PBLS
PK
Relative Strength Index (RSI) 49.52 45.02
Support Level $26.42 $14.59
Resistance Level $41.72 $15.86
Average True Range (ATR) 2.25 0.50
MACD 0.60 -0.11
Stochastic Oscillator 71.30 18.68

Price Performance

Historical Comparison
PBLS
PK

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 19,902 rooms across 29 hotels in the United States. Park also has an interest through a joint venture in another 1,424 rooms in another US hotel. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

Share on Social Networks: